AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase III clinical study titled A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy. The study aims to assess the efficacy and safety of anifrolumab, a subcutaneous injection, compared to a placebo in reducing skin disease in adults with chronic and/or subacute cutaneous lupus erythematosus (CLE) who do not respond to antimalarial therapy.
The intervention being tested is anifrolumab, a combination product administered via subcutaneous injection. It is designed to improve skin conditions in patients with CLE by targeting specific immune pathways.
The study follows a randomized, double-blind, placebo-controlled design with a parallel intervention model. It includes two stages, each with two arms, and aims to treat participants while maintaining masking for both participants and investigators to ensure unbiased results.
The study began on June 29, 2024, with primary completion expected by June 25, 2025. These dates are crucial as they mark the progression and anticipated milestones of the study, providing a timeline for potential results and subsequent market impact.
This study update could influence AstraZeneca’s stock performance positively by showcasing their commitment to advancing treatment options for CLE. Successful outcomes may boost investor confidence and position AstraZeneca favorably against competitors in the pharmaceutical industry.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.